Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04231539 · ClinicalTrials.gov registry record · NA
Pharmacokinetics, Subjective Effects, and Abuse Liability of Nicotine Salt-Based Vaping Products With Tobacco or Unflavored E-liquids, SALTVAPE Study
A NA study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
NCT04231539 is a NA study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 15 participants.
The verdict
NCT04231539, a NA study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
Study Summary
This trial studies activity of time (pharmacokinetics), subjective effects, and abuse liability of nicotine salt-based vaping products with tobacco or e-liquids. This study aims to determine and compare the levels of nicotine delivered to the bloodstream from nicotine salt and free-base nicotine e-liquid solutions.
Interventions
- DRUG Nicotine
- DEVICE Vaporizer Device
- DRUG Salt-HIgh Nicotine Unflavored (Product B)
- DRUG Free-Low Nicotine Tobacco Flavored (Product C)
- DRUG Salt-High Nicotine Tobacco Flavored (Product D)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2020-02-18 |
| Est. Completion | 2024-07-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04231539
The ClinicalTrials.gov registry entry for NCT04231539 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Nicotine is the first listed.
NCT04231539 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04231539 about?
NCT04231539 is a clinical study titled "Pharmacokinetics, Subjective Effects, and Abuse Liability of Nicotine Salt-Based Vaping Products With Tobacco or Unflavored E-liquids, SALTVAPE Study". This trial studies activity of time (pharmacokinetics), subjective effects, and abuse liability of nicotine salt-based vaping products with tobacco or e-liquids. This study aims to determine and compare the levels of nicotine delivered to the bloodstream from nicotine salt and free-base nicotine e-l...
What is the current status of trial NCT04231539?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2020-02-18. Estimated completion is 2024-07-10.
What interventions are being tested in trial NCT04231539?
The interventions under investigation include: Nicotine (DRUG), Vaporizer Device (DEVICE), Salt-HIgh Nicotine Unflavored (Product B) (DRUG), Free-Low Nicotine Tobacco Flavored (Product C) (DRUG), Salt-High Nicotine Tobacco Flavored (Product D) (DRUG).
Who is sponsoring clinical trial NCT04231539?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.